Basic Stats
| LEI | 549300C5ZB4NZ6TWM881 |
| CIK | 1142596 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nuvasive Inc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 |
|
| September 11, 2023 |
NUVA / Nuvasive Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: NuVasive Inc. Title of Class of Securities: Common Stock CUSIP Number: 670704105 Date of Event Which Requires Filing of this Statement: August 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 POS AM As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 S-8 POS As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
AMENDED AND RESTATED BYLAWS NUVASIVE, INC. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NUVASIVE, INC. 1. OFFICES: 1.1. The Corporation may have an office or offices at such places as the Board of Directors may from time to time designate. 2. MEETING OF STOCKHOLDERS: 2.1. The annual meeting of stockholders for the election of directors shall be held at such time and date as may be fixed by the Board of Directors. 2.2. Special meetings of the |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 POS AM As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NUVASIVE, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVASIVE, INC. FIRST: The name of the Corporation is NuVasive, Inc. (the “Corporation”). SECOND: The registered office of the Corporation in the State of Delaware shall be: 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address shall be The Corporation Trust Compan |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
EX-4.1 Exhibit 4.1 Execution Version FIRST SUPPLEMENTAL INDENTURE This FIRST SUPPLEMENTAL INDENTURE, dated as of September 1, 2023 (the “First Supplemental Indenture”), is entered into among NuVasive, Inc., a Delaware corporation (the “Company”), Globus Medical, Inc., a Delaware corporation (“Parent”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Tru |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 POSASR As filed with the Securities and Exchange Commission on September 1, 2023 Registration Nos. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 2, 2023 |
EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces Second Quarter 2023 Financial Results –U.S. Cervical continues to deliver greater than 20% year-over-year growth– –International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO – August 2, 2023 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with m |
|
| August 2, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 19, 2023 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 12101 Airport Way, Broomfield, Colorado 80021 (Address of principal executive |
|
| May 19, 2023 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| May 10, 2023 |
EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces First Quarter 2023 Financial Results –Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis– –U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO – May 10, 2023 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spi |
|
| May 10, 2023 |
NuVasive, Inc. Excise Tax Gross-Up Plan Exhibit 10.4 NUVASIVE, INC. EXCISE TAX GROSS-UP PLAN 1.Purpose; Effective Date. The purpose of this NuVasive, Inc. Excise Tax Gross-Up Plan (the “Plan”) is to make affected employees whole for the impact of the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) with respect to certain compensation and benefits to be paid or provided in connection with |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
First Amendment to the NuVasive, Inc. Amended and Restated Executive Severance Plan Exhibit 10.3 FIRST AMENDMENT TO THE NUVASIVE, INC. AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN NuVasive, Inc. (“NuVasive” or the “Company”) established the NuVasive, Inc. Amended and Restated Executive Severance Plan and Summary Plan Description effective as of July 26, 2007 (the “Plan”). In Article VI of the Plan, the Company, by action of its Board of Directors or Compensation Committee of the |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| May 10, 2023 |
EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 2 TO CREDIT AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AGREEMENT (the “Amendment”), dated as of May 8, 2023, is made by and among NUVASIVE, INC., a Delaware corporation (the “Borrower”), the other Loan Parties (as defined in the Credit Agreement (as defined below)) signatory hereto, BANK OF AMERICA, N.A., in its capacity as administrative agent fo |
|
| May 10, 2023 |
Exhibit 10.5 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS NuVasive, Inc. (the “Company”) has granted to the participant identified below (the “Participant”) an award (the “Award”) of the number of restricted stock units specified below in this Grant Notice (each, a “Restricted Stock Unit” or an “RSU”) pursuant to the [2014 Equity Incentive Plan of NuVasive, Inc.] [Ellipse Tec |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to S ec tion 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Sta |
|
| May 3, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 27, 2023 |
NuVasive Shareholders Approve Merger Agreement with Globus Medical EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Shareholders Approve Merger Agreement with Globus Medical SAN DIEGO, April 27, 2023 — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders |
|
| April 27, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 17, 2023 |
425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 NEWS RELEASE Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote “FOR” the Proposed Merger with Globus Medical SAN DI |
|
| April 17, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 14, 2023 |
425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 NEWS RELEASE Leading Independent Proxy Advisory Firm ISS Recommends NuVasive Shareholders Vote “FOR” the Proposed Merger with Globus Medical SAN DIEGO –April 14, 2023–NuV |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 to Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000- |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 4, 2023 |
425 1 d427723d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporati |
|
| April 4, 2023 |
EX-99.1 Exhibit 99.1 Delivering compelling shareholder value: NuVasive’s combination with Globus Medical April 2023 1 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Safe harbor statements Cautionary notes on forward-looking statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Secu |
|
| April 3, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 3, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 31, 2023 |
425 1 d420993d425.htm 425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Email to all NuVasive Employees Keeping employees updated on the latest integration planning efforts related to the announced combination of NuVasiv |
|
| March 28, 2023 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2023 |
425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 The below provides the transcript from NuVasive’s Q4 2022 earnings call held on February 22, 2023 for parts relating to the discussion of the proposed transaction between N |
|
| February 22, 2023 |
List of subsidiaries of the Company Exhibit 21.1 Subsidiaries of NuVasive, Inc. The following is a list of subsidiaries of the Company as of December 31, 2022, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name Jurisdiction of Incorporation NuVasive Specialized Orthopedics, Inc. Delaware NuVasive Clinical Services Monitoring, Inc. |
|
| February 22, 2023 |
425 Filed by Globus Medical, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Date: February 22, 2023 Globus Medical, Inc. Q4 2022 Earnings Call Transcript February 21, 2023 Company Participants Brian Kearns - Senior Vice President of Business |
|
| February 22, 2023 |
EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces Fourth Quarter and Full-Year 2022 Financial Results and 2023 Net Sales Guidance – Full-year 2022 net sales grew 5.5% as reported, 8.5% on a constant currency basis – – Continued strong international growth in 2022 – – U.S. cervical delivers growth of greater than 20% year-over-year driven by C360 – – 2,000+ Pulse cases performed worldwide since |
|
| February 22, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 22, 2023 |
Table of Contents fv UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 21, 2023 |
425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 NuVasive’s Agreement to Combine with Globus Medical: FAQs for NuVasive employees (revised February 20, 2023) The information in this document is intended to help address qu |
|
| February 17, 2023 |
425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Transcript of Special town hall: NuVasive and Globus joining forces (Feb 16, 2023) [00:00:00] Moran Chavez: Welcome to the special town Hall dedicated to a single topic. An |
|
| February 13, 2023 |
NUVA / NuVasive, Inc. / THRIVENT FINANCIAL FOR LUTHERANS Passive Investment SC 13G 1 tfl13gnuvasive.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NuVasive, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 670704105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 10, 2023 |
425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Combining to create an innovative, global musculoskeletal company focused on patient care February 9, 2023 1 Our vision Diversified, leading musculoskeletal technology comp |
|
| February 9, 2023 |
EX-99.2 Combining to create an innovative global musculoskeletal company February 9, 2023 Exhibit 99.2 Legal disclaimers No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any |
|
| February 9, 2023 |
Exhibit 3.1 AMENDMENT NO. 3 TO THE RESTATED BYLAWS OF NUVASIVE, INC. The following amendment (the “Amendment”) was made to the Restated Bylaws (the “Bylaws”) of NuVasive, Inc. (the “Company”) pursuant to resolutions adopted by the Company’s Board of Directors at a meeting held on February 8, 2023: 1. The following Article X is added to the Bylaws: “Unless the corporation consents in writing to the |
|
| February 9, 2023 |
NUVA / NuVasive, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01547-nuvasiveinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: NuVasive Inc. Title of Class of Securities: Common Stock CUSIP Number: 670704105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rul |
|
| February 9, 2023 |
425 1 d436922d425.htm 425 Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Email to all NuVasive Employees NuVasive, This morning we announced a definitive agreement to combine with Globus Medical. This is an exciting and his |
|
| February 9, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 (February 8, 2023) NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) |
|
| February 9, 2023 |
Exhibit 99.1 Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care Capitalizes on complementary global commercial organizations and accelerates Globus Medical’s and NuVasive’s globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create com |
|
| February 9, 2023 |
Filed by Globus Medical, Inc. pursuant to Rule 425 Filed by Globus Medical, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Date: February 9, 2023 The following e-mail was sent to all employees of Globus Medical, Inc., on February 9, 2023. Sent on behalf of Dan Scavilla At Globus, our mission |
|
| February 9, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commissi |
|
| February 9, 2023 |
Filed by NuVasive, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Globus Medical, Inc. and NuVasive, Inc. Investor Call Transcript February 9, 2022 CORPORATE PARTICIPANTS Brian Kearns Senior Vice President-Business Development, Globus Medical |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 (February 8, 2023) NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) |
|
| February 9, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among GLOBUS MEDICAL, INC., ZEBRA MERGER SUB, INC., and NUVASIVE, INC. dated as of February 8, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01. Certain Definitions 2 Section 1.02. Other Defined Terms 20 Section 1.03. Other Definitional Provisions 23 ARTICLE II THE MERGER 23 Section 2.01. The Merger 23 Section 2.02. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 9, 2023 |
Exhibit 10.1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of February 8, 2023 (the “Agreement Date”), by and among (i) Globus Medical, Inc., a Delaware corporation (“Parent”), (ii) NuVasive, Inc., a Delaware corporation (the “Company”), and (iii) David Paul and Sonali Paul (collectively, the “Stockholders”). Each of |
|
| February 3, 2023 |
US6551871022 / Aclarion Inc / NUVASIVE INC - SC 13G Passive Investment SC 13G 1 d266279dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aclarion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 655187 102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 12, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 12, 2023 |
1 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved. 41st Annual J.P. Morgan Healthcare Conference Chris Barry, Chief Executive Officer January 12, 2023 Exhibit 99.1 2 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Safe harbor statements NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that a |
|
| December 6, 2022 |
NUVA / NuVasive, Inc. / JPMORGAN CHASE & CO - FILING NUVASIVE, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* NUVASIVE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 670704105 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 9, 2022 |
Employment Letter dated August 22, 2022 between the Company and Michael Farrington Exhibit 10.2 August 22, 2022 Michael Farrington Dear Mike, Congratulations on your new full-time, exempt role of Senior Vice President, People and Culture, with NuVasive, Inc. at our San Diego, California site. Our Company?s continued success is dependent on employees like you embodying our core values and working diligently to drive our priorities. In this new role, you will report to me, and we |
|
| November 9, 2022 |
Amendment No. 2 to 2004 Amended and Restated Employee Stock Purchase Plan of NuVasive, Inc. Exhibit 10.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN OF NUVASIVE, INC. WHEREAS, effective as of August 9, 2022 the Board of Directors of NuVasive, Inc. agreed to amend the Amended and Restated 2004 Employee Stock Purchase Plan, as amended from time to time (the ?AR 2004 ESPP?), pursuant to Section 26 of the AR 2004 ESPP. NOW, THEREFORE, the AR 2004 ESPP shall be a |
|
| November 9, 2022 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces Third Quarter 2022 Financial Results ? Net sales grew 9.0% as reported, 12.9% on a constant currency basis ? ? C360 portfolio delivers record quarter in cervical net sales ? ? Company updates full-year 2022 guidance ? SAN DIEGO ? November 9, 2022 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine su |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVAS |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 9, 2022 |
NuVasive Announces Departure of Chief Commercial Officer Exhibit 99.1 NEWS RELEASE NuVasive Announces Departure of Chief Commercial Officer SAN DIEGO ? August 9, 2022 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the resignation of Massimo Calafiore, executive vice president and chief commercial officer, effec |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 3, 2022 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces Second Quarter 2022 Financial Results –Strong year-over-year net sales growth, driven by new product introductions– –Company reiterates full-year guidance range for reported year-over-year net sales growth of 6%–8%– –Company updates full-year guidance range for GAAP diluted EPS; maintains prior non-GAAP diluted EPS range provided May 4, 2022– SAN DIEGO |
|
| July 11, 2022 |
NUVA / NuVasive, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: NuVasive Inc. Title of Class of Securities: Common Stock CUSIP Number: 670704105 Date of Event Which Requires Filing of this Statement: June 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 12101 Airport Way, Broomfield, Colorado 80021 (Address of principal executive |
|
| May 27, 2022 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. EX-1.01 2 exhibit101-conflictmineral.htm EX-1.01 Exhibit 1.01 NuVasive, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2021 to December 31, 2021 This Conflict Minerals Report, or Report, of NuVasive, Inc., or NuVasive, also referred to as “we” or “our”, for the period January 1, 2021 to December 31, 2021, or the Reporting Period, has been prepared pursuant to Rule 13p-1, or |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 4, 2022 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces First Quarter 2022 Financial Results ?Strong year-over-year net sales growth, driven by new product introductions and International sales ? ?Company raises lower end of full-year 2022 financial guidance range ? SAN DIEGO ? May 4, 2022 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with m |
|
| May 4, 2022 |
Exhibit 10.2 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF PERFORMANCE RESTRICTED STOCK UNITS NuVasive, Inc. (the ?Company?) has granted to the participant identified below (the ?Participant?) an award (the ?Award?) of the number of performance restricted stock units specified below in this Grant Notice (each, a ?Performance Restricted Stock Unit? or ?PRSU?) pursuant to the [2014 Equity Incentive Pl |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| May 4, 2022 |
Exhibit 10.3 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS NuVasive, Inc. (the ?Company?) has granted to the participant identified below (the ?Participant?) an award (the ?Award?) of the number of restricted stock units specified below in this Grant Notice (each, a ?Restricted Stock Unit? or an ?RSU?) pursuant to the [2014 Equity Incentive Plan of NuVasive, Inc.] [Ellipse Tec |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 30, 2022 |
DEF 14A 1 d262335ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| February 23, 2022 |
List of subsidiaries of the Company Exhibit 21.1 Subsidiaries of NuVasive, Inc. The following is a list of subsidiaries of the Company as of December 31, 2021, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name Jurisdiction of Incorporation NuVasive Specialized Orthopedics, Inc. Delaware NuVasive Clinical Services Monitoring, Inc. |
|
| February 23, 2022 |
Exhibit 10.28 SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (?Agreement?) is made and entered into by and between Brent Boucher (?Executive?) and NuVasive, Inc. (the ?Company?). WHEREAS, the parties acknowledge and agree that Executive was employed by the Company as an at-will employee, and is an executive eligible for severance pay and benefits under the N |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K fv UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50744 NUVASIVE, I |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 23, 2022 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Outlook ?Pulse platform demonstrates strong performance in early adoption, including first international commercial contracts? ?NuVasive Simplify Cervical Disc exceeds expectations in first year? ?International delivers double-digit net sales growth in 2021? SAN DIEGO ? February 23, 2022 ? NuV |
|
| February 23, 2022 |
Employment Letter dated January 14, 2022 between the Company and Andrew C. Morton Exhibit 10.31 January 14, 2022 Andrew (Drew) Morton Germantown, TN 38139 Dear Drew, NuVasive, Inc. (NuVasive or the Company) is pleased to confirm our verbal offer for the full time, exempt position of Senior Vice President, Chief Human Resources Officer. In this role, you will report to me, and your start date will be February 7, 2022. This offer and your at-will employment relationship with NuVa |
|
| February 11, 2022 |
NUVA / NuVasive, Inc. / HARTFORD MUTUAL FUNDS INC/CT - SC 13G Passive Investment February 11, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 RE: Schedule 13G – Nuvasive Inc. As of: December 31, 2021 In accordance with Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), attached is an initial Schedule 13G for the above named company showing that the reporting person has ceased to be the beneficial owner of more than five |
|
| February 10, 2022 |
NUVA / NuVasive, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: NuVasive Inc. Title of Class of Securities: Common Stock CUSIP Number: 670704105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| January 26, 2022 |
NUVA / NuVasive, Inc. / JPMORGAN CHASE & CO - FILING NUVASIVE, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NUVASIVE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 670704105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 12, 2022 |
Strong foundation for growth ©2022. NuVasive, Inc. or one of its subsidiaries. All rights reserved. 40th Annual J.P. Morgan Healthcare Conference Chris Barry Chief Executive Officer January 12, 2022 ?2022. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Exhibit 99.1 ?2022. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Forward-looking statements NuVasive, Inc. (?NuVasive,? ?NUVA? or the ?Company?) cautions you that statements included in this presentation that ar |
|
| January 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 10, 2021 |
NUVA / NuVasive, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* NuVasive, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 670704105 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) ( |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVAS |
|
| November 9, 2021 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces Third Quarter 2021 Financial Results - Company updates full-year 2021 financial guidance - - Pulse platform launches and completes first commercial cases - - Cervical portfolio delivers double-digit, year-over-year growth in U.S. led by Simplify Cervical Disc - SAN DIEGO ? November 9, 2021 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 13, 2021 |
NuVasive, Inc. September 13, 2021 Investor update ?2021 NuVasive, Inc. or one of its subsidiaries. All rights reserved. Exhibit 99.1 Forward-looking statements and non-GAAP financial measures ?2021 NuVasive, Inc. or one of its subsidiaries. All rights reserved. NuVasive, Inc. (?NuVasive? or the ?Company?) cautions you that statements included in this presentation that are not a description of hist |
|
| September 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 10, 2021 |
NUVA / NuVasive, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* NuVasive, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 670704105 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 1, 2021 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces New Executive Leadership Roles - New roles strengthen innovation and go-to-market execution - - Massimo Calafiore appointed Chief Commercial Officer - - Ryan Donahoe appointed Chief Technology Officer - SAN DIEGO ? September 1, 2021 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with min |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 9, 2021 |
Press release issued by NuVasive, Inc. on August 9, 2021. Exhibit 99.1 NEWS RELEASE Amy Belt Raimundo to Join NuVasive Board of Directors New board member brings extensive knowledge of medical technology and digital health SAN DIEGO ? August 9, 2021 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 28, 2021 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces Second Quarter 2021 Financial Results - Net sales increase driven by recovery across all procedural segments and continued strong international growth - - Pulse platform clinical evaluations underway in Europe following latest CE certification - - Company provides full-year 2021 financial guidance - SAN DIEGO ? July 28, 2021 ? NuVasive, Inc. (NASDAQ: NU |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 7475 Lusk Boulevard, San Diego, California 92121 (Address of principal executi |
|
| May 28, 2021 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. EX-1.01 2 nuva-ex1016.htm EX-1.01 Exhibit 1.01 NuVasive, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2020 to December 31, 2020 This Conflict Minerals Report (the “Report”) of NuVasive, Inc. (“NuVasive,” also referred to as “we,” or “our”) for the period January 1, 2020 to December 31, 2020 (the “Reporting Period”) has been prepared pursuant to Rule 13p-1 (“Rule 13p-1” or |
|
| May 19, 2021 |
NuVasive Appoints Daniel J. Wolterman as Independent Board Chair Exhibit 99.1 NEWS RELEASE NuVasive Appoints Daniel J. Wolterman as Independent Board Chair SAN DIEGO?? May 19, 2021?? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Daniel J. Wolterman as independent chair of the NuVasive Board of Directo |
|
| May 19, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 5, 2021 |
Exhibit 10.1 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF PERFORMANCE RESTRICTED STOCK UNITS NuVasive, Inc. (the ?Company?) has granted to the participant identified below (the ?Participant?) an award (the ?Award?) of the number of performance restricted stock units specified below in this Grant Notice (each, a ?Performance Restricted Stock Unit? or ?PRSU?) pursuant to the [2014 Equity Incentive Pl |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2021 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces First Quarter 2021 Financial Results - Net sales increase driven by U.S. procedural volume improvement throughout the quarter and strong international growth - - Simplify Cervical Artificial Disc receives FDA approval for two-level cervical total disc replacement - - R&D investment increase year over year to advance spine procedural segments and enablin |
|
| May 5, 2021 |
Exhibit 10.2 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS NuVasive, Inc. (the ?Company?) has granted to the participant identified below (the ?Participant?) an award (the ?Award?) of the number of restricted stock units specified below in this Grant Notice (each, a ?Restricted Stock Unit? or an ?RSU?) pursuant to the [2014 Equity Incentive Plan of NuVasive, Inc.] [Ellipse Tec |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant R Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 6, 2021 |
DEF 14A 1 d93713ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant R Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 25, 2021 |
Exhibit 99.1 NEWS RELEASE NuVasive Announces Retirement of Gregory T. Lucier from Board of Directors Mr. Lucier?s commitment to disruptive technology and global scale accelerated Company growth to more than $1 billion in net sales SAN DIEGO ? March 25, 2021 ? NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, p |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) |
|
| February 25, 2021 |
Employment Letter dated January 1, 2019 between the Company and Lucas Vitale Exhibit 10.48 January 1, 2019 Lucas S. Vitale XXX XXX Dear Lucas, Congratulations on your promotion to the role of Leader, Global Human Resources. Your external / business card title is Chief Human Resources Officer. Your commitment and dedication to your work and the continued success of NuVasive sets an example for our Shareowners and is instrumental in our efforts to transform spine surgery and |
|
| February 25, 2021 |
fv UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50744 NUVASIVE, I |
|
| February 25, 2021 |
EX-99.1 2 nuva-ex99115.htm EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces Fourth Quarter and Full Year 2020 Financial Results - Acquires Simplify Medical and the most clinically effective technology in the cervical total disc replacement (cTDR) procedure segment - - Submits 510(k) clearance for Pulse platform and reiterates summer 2021 launch - - Continued to increase R&D investments in 2020 |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 25, 2021 |
Separation Agreement and General Release dated January 28, 2021 between the Company and Matthew Link Exhibit 10.42 SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (?Agreement?) is made and entered into by and between Matthew Link (?Executive?) and NuVasive, Inc. (the ?Company?). WHEREAS, the parties acknowledge and agree that Executive was employed by the Company as an at-will employee, and is an executive eligible for severance pay and benefits under the Nu |
|
| February 25, 2021 |
List of subsidiaries of the Company Exhibit 21.1 Subsidiaries of NuVasive, Inc. The following is a list of subsidiaries of the Company as of December 31, 2020, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name Jurisdiction of Incorporation NuVasive Specialized Orthopedics, Inc. Delaware NuVasive Clinical Services Monitoring, Inc. |
|
| February 25, 2021 |
Exhibit 10.49 October 25, 2019 Dale A. Wolf XXX XXX Dear Dale, Congratulations on your promotion to the role of Leader, Global Operations with NuVasive, Inc. Your external / business card title is Senior Vice President, Global Operations. Your commitment and dedication to your work and the continued success of NuVasive sets an example for our Shareowners and is instrumental in our efforts to trans |
|
| February 24, 2021 |
EX-99.2 3 nuva-ex9927.htm EX-99.2 NuVasive acquires Simplify Medical February 24, 2021 ©2021. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Exhibit 99.2 Safe Harbor Statements Forward-looking information and non-GAAP measures 2 ©2021. NuVasive, Inc. or one of its subsidiaries. All rights reserved. NuVasive, Inc. (“NuVasive” or the “Company”) cautions you that statements included |
|
| February 24, 2021 |
Exhibit 99.1 NEWS RELEASE NuVasive Acquires Simplify Medical Simplify Cervical Artificial Disc provides NuVasive most clinically effective technology in the cervical total disc replacement (cTDR) procedure segment Expands growth opportunities and further differentiates Company’s comprehensive portfolio across ACDF, PCF, and cTDR procedures SAN DIEGO – February 24, 2021 – NuVasive, Inc. (NASDAQ: NU |
|
| February 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: NuVasive Inc. Title of Class of Securities: Common Stock CUSIP Number: 670704105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Nuvasive Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 670704105 (CUSIP Number) 12/31/2020 (Date of Event Which Requires |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* NuVasive, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 670704105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 1, 2021 |
Exhibit 99.1 NEWS RELEASE Dr. Siddhartha Kadia to Join NuVasive Board of Directors New board member brings expertise in commercializing disruptive medical technology SAN DIEGO – February 1, 2021 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointme |
|
| October 29, 2020 |
Exhibit 10.2 EXECUTION VERSION AMENDMENT AGREEMENT dated as of October 26, 2020 Between ROYAL BANK OF CANADA and NUVASIVE, INC. THIS AMENDMENT AGREEMENT (“Amendment Agreement”) with respect to the Warrant Confirmations (as defined below) is made as of October 26, 2020 between NuVasive, Inc. (“Issuer”) and Royal Bank of Canada (“Dealer”), through its agent RBC Capital Markets, LLC (“Agent”). WHEREA |
|
| October 29, 2020 |
EX-10.5 6 nuva-ex10541.htm EX-10.5 Exhibit 10.5 October 14, 2020 Dear Massimo, Congratulations on your new full-time, exempt role of Executive Vice President, Global Business Units, with NuVasive, Inc. at our San Diego, California site. Our Company’s continued success is dependent on Shareowners like you embodying our core values and working diligently to drive our priorities. In this new role, yo |
|
| October 29, 2020 |
Exhibit 10.3 EXECUTION VERSION AMENDMENT AGREEMENT dated as of October 26, 2020 Between BANK OF AMERICA, N.A. and NUVASIVE, INC. THIS AMENDMENT AGREEMENT (“Amendment Agreement”) with respect to the Warrant Confirmations (as defined below) is made as of October 26, 2020 between NuVasive, Inc. (“Issuer”) and Bank of America, N.A. (“Dealer”). WHEREAS, (i) Dealer and Issuer entered into a letter agree |
|
| October 29, 2020 |
EX-10.9 10 nuva-ex10945.htm EX-10.9 Exhibit 10.9 AMENDMENT NO. 1 TO PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT AND RESTRICTIVE COVENANT AGREEMENT THIS AMENDMENT NO. 1 TO PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT AND RESTRICTIVE COVENANT AGREEMENT (this “Amendment”) is made and entered into by and between Matthew Link (“Shareowner”) and NuVasive, Inc. (the “Company”) (collectively “Parties |
|
| October 29, 2020 |
Exhibit 10.6 October 13, 2020 Brent J. Boucher Dear Brent, NuVasive, Inc. (NuVasive or the Company) is pleased to confirm our verbal offer for the full time, exempt position of Executive Vice President, Global Commercial. In this role, you will report to me, and your start date will be October 14, 2020. This offer and your at-will employment relationship with NuVasive will be subject to the terms |
|
| October 29, 2020 |
Exhibit 10.7 October 13, 2020 Dear Matt, This letter agreement confirms the terms of your continuing employment relationship with NuVasive, Inc. (the “Company”). The Compensation Committee of the Company’s Board of Directors (the “Board”) has approved the following amendments to your letter agreement dated October 17, 2018 (the “Employment Letter”), to reflect your transition from your current rol |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 29, 2020 |
Exhibit 10.1 EXECUTION VERSION AMENDMENT AGREEMENT dated as of October 26, 2020 Between MORGAN STANLEY & CO. INTERNATIONAL PLC. and NUVASIVE, INC. THIS AMENDMENT AGREEMENT (“Amendment Agreement”) with respect to the Warrant Confirmations (as defined below) is made as of October 26, 2020 between NuVasive, Inc. (“Issuer”) and Morgan Stanley & Co. International plc (“Dealer”). WHEREAS, (i) Dealer and |
|
| October 29, 2020 |
Exhibit 10.8 GENERAL CONSULTING AND SERVICES AGREEMENT This General Consulting and Services Agreement (“Agreement”) is effective as of October 13, 2020 (the “Effective Date”) by and between NuVasive, Inc. (“NuVasive” or the “Company”) and Matthew Link (“Consultant”) (individually referred to as a “Party” or collectively the “Parties”). WHEREAS, the Parties have entered into that certain letter agr |
|
| October 29, 2020 |
NuVasive Announces Third Quarter 2020 Financial Results Exhibit 99.1 NEWS RELEASE NuVasive Announces Third Quarter 2020 Financial Results SAN DIEGO – October 29, 2020 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2020. Third Quarter 2020 Highlights • Net s |
|
| October 29, 2020 |
Exhibit 10.4 EXECUTION VERSION AMENDMENT AGREEMENT dated as of October 26, 2020 Between BARCLAYS BANK PLC and NUVASIVE, INC. THIS AMENDMENT AGREEMENT (“Amendment Agreement”) with respect to the Warrant Confirmations (as defined below) is made as of October 26, 2020 between NuVasive, Inc. (“Issuer”) and Barclays Bank PLC (“Dealer”), through its agent Barclays Capital Inc. (“Agent”). WHEREAS, (i) De |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVAS |
|
| October 14, 2020 |
EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces New Organizational Structure to Align Global Commercial Operations and Product & Services Organization with Long-Term Strategy Massimo Calafiore promoted to executive vice president, Global Business Units Brent Boucher joins NuVasive as executive vice president, Global Commercial Matt Link to remain with the Company as an advisor through the end |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 10, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF NUVASIVE, INC. NuVasive, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY as follows: 1. The Corporation hereby amends Article IV, Section A of its Restated Certificate of Incorporation (the “Certificate of Incorporation” |
|
| August 4, 2020 |
NuVasive Announces Second Quarter 2020 Financial Results EX-99.1 2 nuva-ex9916.htm EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces Second Quarter 2020 Financial Results SAN DIEGO – August 4, 2020 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2020. Second Qu |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 30, 2020 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant R Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Pro |
|
| July 20, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 20, 2020 |
PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant R Filed by a Party other than the Registrant ☐ Check the appropriate box: R Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| July 20, 2020 |
NuVasive Announces Certain Preliminary Unaudited Second Quarter 2020 Results EX-99.1 2 nuva-ex9916.htm EX-99.1 Exhibit 99.1 NEWS RELEASE NuVasive Announces Certain Preliminary Unaudited Second Quarter 2020 Results SAN DIEGO, July 20, 2020 - NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced certain preliminary unaudited results for the |
|
| June 4, 2020 |
EX-10.4 Exhibit 10.4 EXECUTION VERSION Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Convertible Bond H |
|
| June 4, 2020 |
EX-10.5 Exhibit 10.5 EXECUTION VERSION Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of |
|
| June 4, 2020 |
EX-10.6 7 d939382dex106.htm EX-10.6 Exhibit 10.6 EXECUTION VERSION RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “ |
|
| June 4, 2020 |
EX-10.7 Exhibit 10.7 EXECUTION VERSION Bank of America, N.A. One Bryant Park New York, NY 10036 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Tr |
|
| June 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 4, 2020 |
EX-99.1 Exhibit 99.1 NUVASIVE, INC. ANNOUNCES FULL EXERCISE OF OPTION BY INITIAL PURCHASERS TO PURCHASE ADDITIONAL 1.00% CONVERTIBLE SENIOR NOTES DUE 2023 SAN DIEGO, CA – June 4, 2020 — NuVasive, Inc. (NASDAQ: NUVA) announced today that it closed the issuance of an additional $50.0 million in aggregate principal amount of the 1.00% Convertible Senior Notes due 2023 (the “Convertible Notes”), pursu |
|
| June 4, 2020 |
EX-99.1 NuVasive, Inc. Investor Presentation June 4, 2020 ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Exhibit 99.1 Forward-looking statements ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts a |
|
| June 4, 2020 |
EX-10.8 Exhibit 10.8 EXECUTION VERSION Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Issuer Warrant Tra |
|
| June 4, 2020 |
EX-10.3 Exhibit 10.3 EXECUTION VERSION Bank of America, N.A. One Bryant Park New York, NY 10036 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into o |
|
| June 4, 2020 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and condit |
|
| June 4, 2020 |
EX-10.2 Exhibit 10.2 EXECUTION VERSION RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 June 2, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Additional Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to |
|
| June 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 1, 2020 |
EX-10.3 5 d830681dex103.htm EX-10.3 Exhibit 10.3 EXECUTION VERSION Bank of America, N.A. One Bryant Park New York, NY 10036 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced tran |
|
| June 1, 2020 |
EX-10.7 Exhibit 10.7 EXECUTION VERSION Bank of America, N.A. One Bryant Park New York, NY 10036 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Da |
|
| June 1, 2020 |
EX-4.1 2 d830681dex41.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION NUVASIVE, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION Trustee Indenture Dated as of June 1, 2020 1.00% Convertible Senior Notes due 2023 TABLE OF CONTENTS PAGE ARTICLE 1 Definitions and Incorporation by Reference Section 1.01. Definitions 1 Section 1.02. References to Interest 11 Section 1.03. Rules of Construction 11 ARTICLE 2 The |
|
| June 1, 2020 |
EX-10.5 7 d830681dex105.htm EX-10.5 Exhibit 10.5 EXECUTION VERSION Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the te |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 1, 2020 |
EX-10.8 10 d830681dex108.htm EX-10.8 Exhibit 10.8 EXECUTION VERSION Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: |
|
| June 1, 2020 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions o |
|
| June 1, 2020 |
EX-10.2 4 d830681dex102.htm EX-10.2 Exhibit 10.2 EXECUTION VERSION RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this |
|
| June 1, 2020 |
EX-10.4 6 d830681dex104.htm EX-10.4 Exhibit 10.4 EXECUTION VERSION Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: B |
|
| June 1, 2020 |
EX-10.6 8 d830681dex106.htm EX-10.6 Exhibit 10.6 EXECUTION VERSION RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 May 27, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confir |
|
| May 29, 2020 |
Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 NuVasive, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2019 to December 31, 2019 This Conflict Minerals Report (the “Report”) of NuVasive, Inc. (“NuVasive,” also referred to as “we,” or “our”) for the period January 1, 2019 to December 31, 2019 (the “Reporting Period”) has been prepared pursuant to Rule 13p-1 (“Rule 13p-1” or the “Rule”) under the Securities |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 7475 Lusk Boulevard, San Diego, California 92121 (Address of principal executi |
|
| May 28, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 28, 2020 |
EX-99.1 2 d935561dex991.htm EX-99.1 Exhibit 99.1 NUVASIVE, INC. ANNOUNCES PRICING OF OFFERING OF $400 MILLION OF 1.00% CONVERTIBLE SENIOR NOTES DUE 2023 SAN DIEGO, CA – May 27, 2020 — NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering (the “Offering”) of $400.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2023 (the “Convertible Notes”) in a privat |
|
| May 28, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 26, 2020 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO CREDIT AGREEMENT THIS AMENDMENT NO. 1 TO CREDIT AGREEMENT (the “Amendment”), dated as of May 26, 2020, is made by and among NUVASIVE, INC., a Delaware corporation (the “Borrower”), the other Loan Parties (as defined in the Credit Agreement (as defined below)) signatory hereto, BANK OF AMERICA, N.A., in its capacity as administrative agent for the Lenders (as |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 26, 2020 |
NUVASIVE, INC. ANNOUNCES PROPOSED OFFERING OF $400 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2023 EX-99.1 Exhibit 99.1 NUVASIVE, INC. ANNOUNCES PROPOSED OFFERING OF $400 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2023 SAN DIEGO, CA, May 26, 2020 – NuVasive, Inc. (NASDAQ: NUVA) announced today that it intends to offer (the “Offering”), subject to market and other considerations, $400.0 million aggregate principal amount of Convertible Senior Notes due 2023 (the “Convertible Notes”) in a private pl |
|
| May 6, 2020 |
NuVasive Announces First Quarter 2020 Financial Results Exhibit 99.1 NEWS RELEASE NuVasive Announces First Quarter 2020 Financial Results SAN DIEGO – May 6, 2020 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2020. First Quarter 2020 Highlights • Revenue decrea |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50744 NUVASIVE, |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 6, 2020 |
Exhibit 10.3 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF PERFORMANCE CASH AWARD NuVasive, Inc. (the “Company”) has granted to the participant identified below (the “Participant”) a performance cash award (the “Award”) pursuant to the NuVasive, Inc. 2014 Equity Incentive Plan (the “Plan”), which represents the right to receive – on the Settlement Date provided in the Performance Cash Award Agreemen |
|
| May 6, 2020 |
Exhibit 10.2 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS NuVasive, Inc. (the “Company”) has granted to the participant identified below (the “Participant”) an award (the “Award”) of the number of restricted stock units specified below in this Grant Notice (each, a “Restricted Stock Unit” or an “RSU”) pursuant to the [2014 Equity Incentive Plan of NuVasive, Inc.] [Ellipse Tec |
|
| May 6, 2020 |
Exhibit 10.1 [FORM OF] NUVASIVE, INC. NOTICE OF GRANT OF PERFORMANCE RESTRICTED STOCK UNITS NuVasive, Inc. (the “Company”) has granted to the participant identified below (the “Participant”) an award (the “Award”) of the number of performance restricted stock units specified below in this Grant Notice (each, a “Performance Restricted Stock Unit” or “PRSU”) pursuant to the [2014 Equity Incentive Pl |
|
| May 6, 2020 |
Exhibit 10.5 SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is made and entered into by and between Rajesh J. Asarpota (“Employee”) and NuVasive, Inc. (the “Company”). WHEREAS the parties acknowledge and agree that Employee was employed by the Company as an at-will employee, and is an executive eligible for severance pay and benefits under the |
|
| May 6, 2020 |
Exhibit 10.4 April 13, 2020 [NAME] NuVasive, Inc. Re: NuVasive, Inc. – Temporary Reduction of Compensation Dear [NAME]: In light of the COVID-19 pandemic and its potential impact on the Company’s business and industry, and the economy in general, NuVasive is taking a number of actions to support the health and well-being of our Shareowners, address the financial impacts of COVID-19 and the disrupt |
|
| April 16, 2020 |
NUVA / NuVasive, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 16, 2020 |
NUVA / NuVasive, Inc. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 NuVasive, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 14, 2020 |
Exhibit 99.1 NEWS RELEASE NuVasive Provides Business Update Related to COVID-19 Announces preliminary first quarter 2020 revenue results and actions to align expenses with anticipated market conditions SAN DIEGO, April 14, 2020 - NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutio |
|
| April 9, 2020 |
NUVA / NuVasive, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: NuVasive Inc Title of Class of Securities: Common Stock CUSIP Number: 670704105 Date of Event Which Requires Filing of this Statement: March 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| March 2, 2020 |
EX-10.5 7 d873711dex105.htm EX-10.5 Exhibit 10.5 EXECUTION COPY Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: |
|
| March 2, 2020 |
EX-10.10 Exhibit 10.10 EXECUTION COPY Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Trans |
|
| March 2, 2020 |
EX-4.1 2 d873711dex41.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION NUVASIVE, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION Trustee Indenture Dated as of March 2, 2020 0.375% Convertible Senior Notes due 2025 TABLE OF CONTENTS PAGE ARTICLE 1 Definitions and Incorporation by Reference Section 1.01. Definitions 1 Section 1.02. References to Interest 11 Section 1.03. Rules of Construction 11 ARTICLE 2 T |
|
| March 2, 2020 |
EX-10.7 Exhibit 10.7 EXECUTION COPY JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Telephone: 858-909-1847 Facsimile: 800-475-9134 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth |
|
| March 2, 2020 |
EX-10.4 Exhibit 10.4 EXECUTION COPY The Bank of Nova Scotia 44 King Street West Central Mail Room Toronto, Ontario, Canada M5H 1H1 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-ref |
|
| March 2, 2020 |
EX-10.6 Exhibit 10.6 EXECUTION COPY Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 2, 2020 |
EX-10.8 10 d873711dex108.htm EX-10.8 Exhibit 10.8 EXECUTION COPY RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this |
|
| March 2, 2020 |
EX-10.1 Exhibit 10.1 EXECUTION COPY Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions |
|
| March 2, 2020 |
EX-10.2 4 d873711dex102.htm EX-10.2 Exhibit 10.2 EXECUTION COPY JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Telephone: 858-909-1847 Facsimile: 800-475-9134 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communicatio |
|
| March 2, 2020 |
EX-10.11 Exhibit 10.11 AMENDMENT AGREEMENT dated as of February 26, 2020 Between BANK OF AMERICA, N.A. and NUVASIVE, INC. THIS AMENDMENT AGREEMENT (“Amendment Agreement”) with respect to the Warrant Confirmations (as defined below) is made as of February 26, 2020 between NuVasive, Inc. (“Issuer”) and Bank of America, N.A. (“Dealer”). WHEREAS, (i) Dealer and Issuer entered into a letter agreement d |
|
| March 2, 2020 |
EX-10.3 5 d873711dex103.htm EX-10.3 Exhibit 10.3 EXECUTION COPY RBC Capital Markets, LLC as Agent for Royal Bank of Canada Brookfield Place 200 Vesey Street New York, NY 10281-1021 Telephone: (212) 858-7000 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Convertible Bond Hedge Transaction Dear Ladies and Gentlemen: The purpose of this communication (th |
|
| March 2, 2020 |
EX-10.9 Exhibit 10.9 EXECUTION COPY The Bank of Nova Scotia 44 King Street West Central Mail Room Toronto, Ontario, Canada M5H 1H1 February 26, 2020 To: NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Re: Base Issuer Warrant Transaction Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced |
|
| February 27, 2020 |
EX-99.1 Exhibit 99.1 NUVASIVE, INC. ANNOUNCES PRICING OF OFFERING OF $450 MILLION OF 0.375% CONVERTIBLE SENIOR NOTES DUE 2025 SAN DIEGO, CA – February 26, 2020 — NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the “Convertible Notes”) in a private placement to qualified institutional b |
|
| February 27, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 NUVASIVE, INC. (Exact name of registrant as specified in its charter) Delaware 000-50744 33-0768598 (State or Other Jurisdiction of Incorporation) (Commission File N |
